Muhammad Mohiuddin Named for Co-Leading Team that Performed First Genetically-Modified Pig Heart into Human Patient
BALTIMORE, Dec. 19, 2022 /PRNewswire/ — The world-renowned journal Nature, named Muhammad Mohiuddin, MD, DSc, Program and Scientific Director of the Cardiac Xenotransplantation Program at the University of Maryland School of Medicine (UMSOM), on its annual list of 10 people who helped shaped science in 2022. His pivotal work over the past three decades transplanting genetically-modified pig hearts into non-human primates led to the historic xenotransplant of a pig heart into a human patient this past January. The surgery was led by Bartley Griffith, MD, the Thomas E. and Alice Marie Hales Distinguished Professor of Transplant Surgery and Clinical Director of the Cardiac Xenotransplantation Program, who was also recognized by Nature for his ground-breaking efforts to move the field of transplantation into a new era.
“In a year full of crises and stunning discoveries, this year’s Nature‘s 10 list features an astronomer who helped open a window into the distant reaches of the Universe, researchers who had pivotal roles in confronting the COVID-19 pandemic and the mpox outbreak, and a surgeon who pushed the limits on organ transplantation,” said Rich Monastersky, chief features editor at Nature, in a release announcing the 2022 list. “The stories of the people featured in Nature‘s 10 provide unique glimpses into some of the biggest events in science during this extraordinary year.”
Other top 10 leaders include:
Astronomer Jane Rigby, PhD, at NASA’s Goddard Space Flight Center in Greenbelt, Maryland, who played a pivotal part in getting the James Webb Space Telescope into space and working, providing vast new capabilities for studying the Universe.
Saleemul Huq, PhD, director of the International Centre for Climate Change and Development in Dhaka, Bangladesh, who helped win commitments from wealthy nations to pay for losses and damages from climate change during international negotiations last month.
Genomics researcher Yunlong Cao, PhD, microbiologist at Peking University who has helped track the evolution of the SARS-CoV-2 virus and predicted some of the mutations that are fuelling the rise of new variants.
The historic xenotransplant surgery was conducted on January 7, 2022, by University of Maryland School of Medicine (UMSOM) faculty at the University of Maryland Medical Center (UMMC), together known as the University of Maryland Medicine. The surgery was the only available treatment option for the patient, David Bennett, who did not qualify for a traditional heart transplant and was in end-stage heart failure, nearing the end of his life. The procedure was authorized by the U.S. Food and Drug Administration under its expanded access (compassionate use) provision.
Prior to the transplant, Mr. Bennett was bedridden for eight weeks with a life-threatening arrythmia and was connected to a heart-lung bypass machine, called extracorporeal membrane oxygenation (ECMO), to remain alive. Within days of the transplant, he was weaned from ECMO and participated in active rehabilitation for nearly two months. He visited regularly with family members and sang along to “America the Beautiful” while watching the Super Bowl in February with his physical therapist. Dr. Mohiuddin, Dr. Griffith, and their colleagues published their initial findings on the transplant last June in the New England Journal of Medicine. Co-authors included: Corbin Goerlich, MD, PhD, Surgical Resident and Doctoral Fellow, Avneesh Singh, PhD, Immunologist and Assistant Professor in Department of Surgery, Aakash Shah, MD, Cardiac Surgery Resident in the Department of Surgery, Alison Grazioli, MD, Assistant Professor of Medicine and Medical Director of the Cardiac Surgery Intensive Care Unit at UMMC, Susie Hong, MD, Cardiologist, Assistant Professor of Medicine, and Susan Joseph, MD, Cardiologist, Associate Professor of Medicine and Section Chief, Advanced Heart Failure and Transplant Team at UMMC.
“This honor points to the culmination of years of highly complex research to hone the surgical technique and immunosuppressive regimen in non-human primates,” said Mark T. Gladwin, MD, Vice President for Medical Affairs, University of Maryland, Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. “The historic surgery in Mr. Bennett brought us one step closer to enabling it to one day become the standard of care for patients in need of organ transplants.”
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world — with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.
View original content:https://www.prnewswire.com/news-releases/um-school-of-medicine-surgeon-scientist-named-one-of-natures-10-people-who-helped-shape-the-science-stories-of-2022-301705506.html
SOURCE University of Maryland School of Medicine
Madrigal scored a win in the particularly tricky NASH field on Monday after its study hit both its goals, sending MDGL stock flying.
Ardelyx Inc (NASDAQ: ARDX) shares are down after an update regarding the appeal to the Complete Response Letter (received in July 2021) for the marketing application seeking approval for Xphozah (tenapanor). Peter Stein, Director of the Office of New Drugs, Center for Drug Evaluation and Research of the FDA, requested a meeting with Ardelyx to discuss the status of his review of the appeal. Dr. Stein communicated that the FDA is finalizing the response and may require up to a few more weeks to d
(Bloomberg) — Madrigal Pharmaceuticals Inc. shares surged 268%, adding about $2.9 billion to its market value, after a late-stage clinical trial of its drug candidate met the main goals in patients with a type of liver disease.Most Read from BloombergMusk Polls Twitter to Quit as Chief, Voters Leaning Toward YesJustin Bieber Urges Fans Not to Buy His Own ‘Trash’ Merchandise at H&MTwitter Users Vote for Elon Musk to Step Down as CEOMusk Says Twitter Will Restrict Voting on Policy to Blue Members
IceCure Medical, a little-known medical device company surged in after-hours trading Monday. IceCure's Prosense technology proved to be a safe and effective treatment for cancerous kidney tumors.
The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.
A late-stage trial of its drug resmetirom showed a 'best-case dataset' in resolving NASH and improving liver fibrosis.
One in four Britons would not take up the offer of a flu jab, according to a survey, as a think tank called for a permanent health disinformation unit to be launched by Government.
By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT Bria-IMT Breast Cancer Efficacy Data BriaCell (NASDAQ:BCTX) attended the 2022 San Antonio Breast Cancer Symposium in early December and presented several posters summarizing data from its Phase I/IIa clinical study of Bria-IMT and reviews preclinical efforts for the company’s next generation of products. In addition to
For a company like Vertex Pharmaceuticals (NASDAQ: VRTX), 10 years isn't a long time. The drug-development process takes between 12 and 14 years, on average, around 8 years of which are devoted to clinical-stage testing and the regulatory-review process.
Many cities are changing how they respond to mental health calls, but less attention has been paid to the unique risks for people with brain diseases.
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) reported results from a Phase 3 study of Fanapt (iloperidone tablets), a novel atypical antipsychotic, in acute manic and mixed episodes associated with bipolar I disorder in adults. Fanapt is currently approved by the FDA for schizophrenia in adults. In the clinical study VP-VYV-683-3201, approximately 400 volunteers with a history of bipolar I disorder suffering from a current episode of mania were randomized to receive either Fanapt or a placebo. The p
Bodies are piling up in Chinese morgues and crematoriums amid signs that Beijing is covering up the true scale of Covid-related deaths following the sudden relaxation of President Xi Jinping’s zero-Covid policy.
Telus's health division has partnered with Desjardins and Walmart Canada
Welp, now I'm worried about my health since I found out social isolation and loneliness cause a 29% greater risk of heart attack.View Entire Post ›
CVS and Walgreens recently put limits on purchases of children's pain relief medication amid a rise in respiratory illnesses such as the flu and RSV.
The bear market has weighed on stocks across industries this year. Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX) have both climbed in the double digits — and for good reason. Which one of these top stocks represents the better bear market buy right now?
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication – the adjunctive treatment of patients with MDD.
Caring for sick children has become extra stressful recently for many U.S. parents due to shortages of Children’s Tylenol and other medicines.
Consider this the ultimate guide to the in-office treatment that provides bloody-good hair results.
